Video
Shahram Lavasani, Founder & CEO at ImmuneBiotech AB, spoke about how the research in gut-brain axes could pave the way to new microbiome based therapies in neurodegenerative diseases.
Tim Sharpington, Chief Executive Officer at Microbiotica, talked about how the microbiome field should navigate through a difficult financing horizon.
Clara Desvignes, Head of Microbiome at VCLS, spoke about the continuously evolving regulatory landscape on Fecal Microbiome Transplant.
Christopher Reyes, CEO, Co-Founder and Director at Bloom Science, spoke about the new class of microbe-based therapeutics for neurological disorders the company is working on.
Herve Affagard, Chief Executive Officer at MaaT Pharma, gives us an update on the clinical trials (Maat013 and Maat033) and describes the vision of the company for the future of the…
MicrobiomePost discussed with Claire Derlot, Head of Programs at Biose Industrie, the GMP challenges when you have to go from bacteria to a drug.
MicrobiomePost talked with Isabelle de Cremoux, CEO of Seventure Partners, about the news that will emerge in 2023.
Leigh Frame, Director, Integrative Medicine, GW School of Medicine & Health Sciences in Washington, discussed how to exploit metabolomic and genomic data to identify diet-specific signatures.
According to Christoph Lacroix (ETH Zurich), bifidobacteria are critical in the development of the neonatal microbiota. Here's why.
Savita Bernal, Chief Business Officer at MaaT Pharma, discussed the Phase 3 trial (ARES) in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement.
